Posted: August 11, 2009

Eli Lilly and Nanosphere Collaborate on Use of Pharmacogenetic Assays in Drug Development

(Nanowerk News) Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, announced today that it has entered into an agreement with Eli Lilly and Company to collaborate in connection with employing pharmacogenetic assays in drug development initiatives. The two companies have signed the agreement and the financial terms were not disclosed.
Nanosphere is developing the pharmacogenetic assays for use with its new Verigene SP® system -- a sample-to-result, bench top molecular diagnostics instrument. The turnkey and random access system uses whole blood and requires no PCR. It allows for broad dissemination to recruitment sites which have no molecular laboratories or to facilities already performing genetic testing.
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL.
Source: Nanosphere (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: